Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vaminolac is a specialized intravenous amino acid solution designed for use in neonates and infants requiring parenteral nutrition. It provides a balanced mixture of essential, semi-essential, and non-essential amino acids, tailored to the specific metabolic requirements of premature and term babies to support growth and development. The formulation is often utilized in neonatal intensive care units (NICU) and pediatric surgery settings to provide a nitrogen source for protein synthesis. Vaminolac is specifically formulated to be compatible with other components of total parenteral nutrition (TPN), such as glucose and lipids. Clinical research has evaluated its metabolic impact on insulin secretion (the incretin effect) and its safety profile regarding complications like neonatal cholestasis and mineral solubility in pediatric prescriptions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Vaminolac.